References
- Pagano L, Klain M, Pulcrano M, et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004;29:161–74
- Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:62–9
- Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119: 492–502
- Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Eur J Endocrinol 1994;130:350–6
- Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes 2003;111:455–70
- Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152:1–9
- Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:1–33
- Chen CH, Chen JF, Yang BY, et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 2004;103:442–7
- Heijckmann AC, Huijberts MS, Geusens P, et al. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005;153:23–9
- Mikosch P, Jauk B, Gallowitsch HJ, et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 2001;11:257–63
- Franklyn JA, Betteridge J, Daykin J, et al. Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9–13
- Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991;72:1184–8
- Pioli G, Pedrazzoni M, Palummeri E, et al. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh) 1992;126:238–42
- McDermott MT, Perloff JJ, Kidd GS. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 1995;56:521–5
- Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83:2324–30
- Salamone LM, Cauley JA, Black DM, et al. Effect of a lifestyle intervention on bone mineral density in premenopausal women: a randomized trial. Am J Clin Nutr 1999;70:97–103
- Orozco P, Nolla JM. Associations between body morphology and bone mineral density in premenopausal women. Eur J Epidemiol 1997;13:919–24
- Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998;128:386–94
- Sert M, Tetiker T. Effects of L-thyroxine suppressive therapy on bone mineral density. Ann Med Sci 2002;11:21–4
- Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259:3137–41
- Ross DS, Neer RM, Ridgway EC, et al. Subclinical hyper-thyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987;82:1167–70